ArticlePsychiatry investigation2019
Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art.
Article in Psychiatry investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Stigma and health outcomes in multiple sclerosis: a systematic review.BMC neurology · 2024Pooled it
- Best practice exercise for emerging depression in multiple sclerosis: A systematic review and meta-analysis.Clinical rehabilitation · 2024Pooled it
- Pooled it
- Trial
- Clinical trajectories and genetic architecture across the neurological-psychiatric boundary.medRxiv : the preprint server for health sciences · 2026Article
- Editorial for the Special Issue "Cognitive Impairment and Neuropsychiatric Dysfunctions in Multiple Sclerosis (Volume II)".NeuroSci · 2026Article
- Sex Differences in the Neuropsychiatric Symptoms of Multiple Sclerosis: Symptômes neuropsychiatriques de la sclérose en plaques: différences selon le sexe.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2026Article
- MRI Correlates of Depression and Anxiety in Multiple Sclerosis.Diseases (Basel, Switzerland) · 2026Review
- Prevalence and risk factors of bipolar disorder in central nervous system autoimmune demyelinating diseases.BMC psychiatry · 2026Article
- Effects of Transcutaneous Spinal Direct Current Stimulation on Cognitive and Psychological Outcomes in Multiple Sclerosis: A Preliminary Case Series.Biomedicines · 2026Article
- Dynamic Triangulation of Resting-State Networks and CSF Metabolites Reveals Bidirectional Causal Pathways in Multiple Sclerosis: A Mendelian Randomization Analysis.Journal of molecular neuroscience : MN · 2026Article
- Investigating Depression and MRI Associations in Middle Eastern Relapsing-Remitting Multiple Sclerosis.Journal of biomedical physics & engineering · 2026Article
- Differential Associations Between Perceived Social Support and Cognition in Older Adults With and Without Multiple Sclerosis.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Mesenchymal stem cells and the central nervous system: historical perspectives and future directions.Frontiers in molecular neuroscience · 2026Review
- Article
- Trends in Neuropsychiatric Terminology Use Within Registered Clinical Trials for Multiple Sclerosis: A Retrospective Descriptive Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Multiple Sclerosis in the Emergency Department: A Retrospective Case-Control Study in a Large US Center.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Burden, stress, and quality of life among elderly caregivers of persons with neuropsychiatric disorder: A cross-sectional study.Journal of family medicine and primary care · 2025Article
- Fasting, ketogenic, and anti-inflammatory diets in multiple sclerosis: a randomized controlled trial with 18-month follow-up.BMC nutrition · 2025Article
- Age-Onset-Related Particularities of Pediatric MS-Understanding the Spectrum: A Tertiary Center Experience.Diseases (Basel, Switzerland) · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) is a chronic disabling neuroinflammatory disease. Psychiatric manifestations have a high prevalence in MS patients and may worsen the illness progression and the patients' quality of life (QoL). Depression is a highly prevalent condition in MS patients, associated with poorer adherence to treatment, decreased functional status and QoL, and increased suicide risk. Diagnosis and treatment of this disorder is challenging because of symptom overlap. Other prevalent psychiatric comorbidities are anxiety disorders, bipolar disorder, psychotic disorders, substance misuse and personality disorders. As the illness progresses, personality changes can happen, as well as affect abnormalities. Cognitive changes occur frequently in MS patients, and affect features like processing speed, attention, learning, memory, visual spatial capabilities, and some language deficits. Disease-modifying treatments may reduce cognitive impairment because of their container action on the brain's lesion burden. Other QoL determinants such as fatigue, pain, sexual dysfunction, exercise, resilience and social support should be taken into account, in order to promote the individuals' well-being. Further studies are needed in order to elucidate the effectiveness of pharmacotherapy and more neuroimaging studies are required to clarify the relationship between structural changes and psychiatric comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.